Michael Trauner |
, Austria |
Chair(s) |
||||
|
Part 2 chair -
Research Think Tank - Autoimmune and cholestatic liver diseases Workshop |
10 April 2019 08:00 - 11:00 | More ... | ||
|
Chair -
Parallel session: Autoimmune and cholestasis I Science/Research |
11 April 2019 16:00 - 18:00 | More ... | ||
|
Chair -
Pros & Cons Session: PBC patients with inadequate response to UDCA: obeticholic acid or bezafibrate? Workshop |
14 April 2019 10:30 - 11:30 | More ... | ||
|
Chair -
Meet the Experts: Management of non response to therapy in PBC patients Meet the Experts |
14 April 2019 09:30 - 10:20 | More ... | ||
Presentations |
||||
| Shared mechanisms in cholestatic and fatty liver disease - implications for current and future treatment | 12 April 2019 10:30 - 11:00 | More ... | ||
| Methylation signatures in blood show accelerated epigenetic aging in patients with primary sclerosing cholangitis compared to healthy controls | 11 April 2019 09:00 - 19:00 | More ... | ||
Abstracts
| Glucagon like peptide-2 treatment improves liver and bile duct injury in the Mdr2-/- mouse model of sclerosing cholangitis | Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology | More | |
| Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through anti-inflammatory bile acid composition and signaling | Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology | More | |
| Loss of bile salt export pump (Bsep/Abcb11) aggravates lipopolysaccharide induced hepatic inflammation in mice | Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology | More |